Topical anaesthesia

PreclinicalSmall molecule

IIuliu Hatieganu University of Medicine and Pharmacy

Topical anaesthesia is one of 10 small molecule programs targeting Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TumorsCompleted

TumorsPreclinical

Completed

Competition

Competitive Landscape

11 competitors in Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

3 2

Opdivo

Bristol-Myers Squibb

Phase 2

2 3

Yervoy

Bristol-Myers Squibb

Phase 2

2 4

Fludara

Sanofi

Phase 2

1 5

Proleukin

IIovance Biotherapeutics, Inc.

Phase 2

1 6

Tazverik

EEpizyme, Inc.

Phase 2

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 8

Lynparza

AstraZeneca

Preclinical

1 9

Lu-177-DOTATATE

NNational Cancer Institute (NCI)

Preclinical

1 10

Topical anaesthesia

IIuliu Hatieganu University of Medicine and Pharmacy

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tumors1 trial

Awake Nasal Intubation in Laryngopharyngeal Tumors

Completed·IIuliu Hatieganu University of Medicine and Pharmacy·N/A·NCT03546088·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Topical anaesthesia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Topical anaesthesia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Topical anaesthesia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Iuliu Hatieganu University of Medicine and Pharmacy company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIuliu Hatieganu University of Medicine and Pharmacy

Topical anaesthesia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tumors1 trial

References

Drug Info

Quick Facts

Related News